H.C. Wainwright lowered the firm’s price target on Aethlon Medical to $23 from $90 and keeps a Buy rating on the shares following the reverse 1-for-10 stock split. The analyst notes that Hemopurifier has FDA breakthrough device designation in the U.S. It expects longer timeframes to be associated with Hemopurifier regulatory approval, notably, authorization in 2025 versus its prior projection of 2024 for Hemopurifier use in patients with severe or life-threatening COVID-19, and FDA approval in 2028 versus a prior projection of 2025 in oncology indications.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AEMD:
- Aethlon Medical cleared in India to conduct Phase 1 trial of Hemopurifier
- Aethlon Medical announces 1-for-10 reverse stock split
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue